(Q79634770)
English
Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen
scientific article published on 24 January 2007
Statements
Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial (English)
Gershon Y Locker
Robert Mansel
David Cella
Deborah Dobrez
Sonja Sorensen
Sanjay K Gandhi
ATAC Trialists' Group
24 January 2007